State of Minnesota Moves to Adopt Treatment Parameters for Posttraumatic Stress Disorder (PTSD)
The State of Minnesota Department of Labor & Industry has proposed expedited rules governing the treatment of posttraumatic stress disorder (PTSD), known formally as treatment parameters. This action was compelled by the legislative amendments in Minn. Stat. §176.83, Subd. 5(b)(8). The proposed treatment parameters were published in the State Register on November 12, 2019 and are currently open for public comment. The period for public comment ends December 12, 2019.
As with all treatment parameters, these rules only apply when there is not a primary liability dispute. If primary liability is denied, the Employer and Insurer cannot use the treatment parameters as either a sword or a shield regarding the Employee’s treatment.
The proposed treatment parameters are rather straightforward. The Employee must undergo an initial evaluation by a qualified mental health provider. Said evaluation must take account of various factors, including family history, functional status, potential comorbidities or contraindications, etc. The provider must then establish a treatment plan, including the proposed frequency of treatment, the goals of treatment, and a proposed timeline for treatment. Importantly, the treatment plan must specifically address the Employee’s return to work, including any restrictions necessary for return to work.
The proposed rules also require that the provider use a peer-review validated tool when making assessments regarding the Employee’s PTSD, the symptoms related to the same, and the severity thereof. Several examples are provided.
The proposed rules specifically establish the following modalities as appropriate for treatment of PTSD, whether singularly or concurrently:
- Cognitive behavioral therapy (CBT);
- Cognitive processing therapy (CPT);
- Cognitive therapy (CT);
- Prolonged exposure therapy (PE);
- Brief electric psychotherapy (BEP);
- Eye-movement desensitization and reprocessing (EMDR); and
- Narrative exposure therapy (NET).
The proposed rules further indicate that the Employee may be provided “any other treatment modality recommended by the treating mental health care provider that is an evidence-based, trauma-focused psychotherapy treatment modality, subject to [prior notification].”
Under the proposed rules, all treatment must be rendered by a mental health care provider with specific up-to-date training on the treatment of PTSD. The provider must, at least once every two weeks, do the following: reassess the severity of the Employee’s symptoms, adjust the treatment plan as necessary, and complete and submit to the Employee a report of work ability.
The proposed rules also address the duration of treatment. Generally, said treatment is limited to a period of 16 weeks. However, treatment may be extended additional periods, each 16 weeks long, under certain circumstances, including:
- if treatment was interrupted;
- if treatment is working (i.e., the Employee’s symptoms are decreasing, functional status is increasing, and this pattern is expected to continue with further treatment);
- the Employee has returned to work and experienced an exacerbation of PTSD symptoms as a result thereof, such that additional treatment is necessary; or
- upon the order of the commissioner or a compensation judge in “rare case with exceptional circumstances.”
Under the proposed rules, the provider must provide prior notification to the payer (i.e., the Insurer) of each additional 16-week period of treatment. Prior notification must specify what modalities are to be used during the next period and the proposed duration of treatment. Prior notification must be provided, either orally or in writing, to the payer at least 7 working days prior to the planned commencement of the new treatment period. The payer then has to respond within 7 working days. The payer can either approve the treatment, deny the treatment, schedule an independent medical examination, or request additional information. If the payer does not respond in one of these ways within 7 working days, it is deemed to have authorized the proposed treatment.
The proposed rules also place restrictions on the Employee’s ability to change providers. These are akin to the rules generally governing change of providers.
The use of medications for the treatment of PTSD are also addressed in the proposed rules. Of note, the proposed rules require a provider to first consider psychotherapy treatment before prescribing medication (i.e., if the Employee is not receiving psychotherapy treatment, the provider must consider whether it would benefit the Employee before prescribing any medication). The proposed rules indicate that the following medications are indicated for the initial treatment of PTSD:
- Selective serotonin reuptake inhibitors (SSRIs);
- Selective norepinephrine reuptake inhibitors (SNRIs); and
- Antihypertensive medication.
If the above-listed medications are contraindicated, produce undesirable side effects, or fails to decrease the severity of the Employee’s PTSD symptoms, the proposed rules indicate that the following medications are indicated:
- Serotonin antagonist and reuptake inhibitors (SARIs); and
- Other medications prescribed by or in consultation with a psychiatrist or a psychiatric mental health advanced practice registered nurse (PMH-APRN).
Any medications prescribed for the treatment of PTSD must be prescribed at the lowest clinically effective does, for the shortest duration needed, and limited to one period of three months and refills of no more than six months. The use of generic medications is indicated.
Under the proposed rules, the use of benzodiazepines is not appropriate for treatment of PTSD.
With regard to enforcement, under the proposed rules, any Employee treating for PTSD when the rules go into effect, as well as the Employee’s provider(s), must be provided written notice of the rules before the payer can issue any denial on the basis of the rules. No denials can be issued on the basis of the rules until 90 days after notice of the rules is provided by the payer.
Please contact Michael R. Johnson with any questions regarding the proposed rules or any other questions you may have regarding PTSD claims.
The proposed rules (i.e., treatment parameters) can be found here: